<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633957</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-XZ001</org_study_id>
    <nct_id>NCT01633957</nct_id>
  </id_info>
  <brief_title>A Trial of Genotype-based Warfarin Initiation in Patients With Mechanical Prosthetic Heart Valve</brief_title>
  <acronym>SYSU-WARFA</acronym>
  <official_title>Academic Leader，Head of Cardiac Surgery,Principal Investigator, Clinical Professor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until very recently, warfarin is still the best drug of choice for long-term anticoagulation
      for patients with mechanical prosthetic heart valve. However, the complication of warfarin
      account for 75 percent of the whole complication after the mechanical prosthetic heart valve
      replacement.

      Interindividual variation in warfarin dose is mediated by multiple factors.Advanced models
      using combinations of clinical attributes and genetic factors(CYP2C9, VKORC1, and CYP4F2)
      explain 50-75% of variability in warfarin dose requirements.These warfarin dosing models have
      the potential to improve patient safety by reducing or eliminating serious adverse events.
      The investigators conducted a prospective, randomized, blinded, two arm trial to test this
      hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to steady dosage</measure>
    <time_frame>from seven days after the operation to thirty days after the operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time in Therapeutic Range</measure>
    <time_frame>from five days after the operation to thirty days after the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>first time to treatment window</measure>
    <time_frame>from five days after the operation to thirty days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ratio of INR≥3.0 and INR≤1.5</measure>
    <time_frame>from five days after the operation to thirty days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the monitoring frequency of INR</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the whole-cause mortality</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding event</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major thrombosis rate</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute difference between the stable dose and initial dose</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of dosage change</measure>
    <time_frame>30 days after the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anticoagulation Treatment Overdose</condition>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>Genotype-based Warfarin Initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clinical factor-based warfarin initiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genotype-based Warfarin Initiation model</intervention_name>
    <description>Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.</description>
    <arm_group_label>Genotype-based Warfarin Initiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical factor-based warfarin initiation model</intervention_name>
    <description>Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.</description>
    <arm_group_label>clinical factor-based warfarin initiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the first time to receive elective mitral and/or aortic mechanical prosthetic valve
             replacement

          -  willing to join in the clinical trial and comply with the protocol.

        Exclusion Criteria:

          -  other ethnic groups than Han

          -  previously receive any other cardiac surgery

          -  emergent surgery

          -  simultaneously carry out other cardiac surgeries,such as CABG

          -  age younger than 18y or older than 65 year

          -  drug abuser and wine abuser

          -  any malignancy

          -  moderate or severe hepatic or kidney insufficiency

          -  any thyroid disease

          -  the history of warfarin or VitK consumption 2 week before the surgery

          -  any hematological disease or history of bleeding

          -  combination with any drugs that significantly influence warfarin other than Cordarone

          -  pregnancy

          -  any contraindication of warfarin

          -  infectious endocarditis

          -  advanced valvular disease

          -  pathological obesity

          -  psychological disease

          -  any patient having joined in other clinical trial in the previous 30d

          -  basic INR &gt; 1.4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Zhang, MD.</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhe Xu, MD. ,PHD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Zhang, MD.</last_name>
    <phone>86-13902279690</phone>
    <email>zhangxisysu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhe Xu, MD. ,PHD.</last_name>
    <phone>86-13828453339</phone>
    <email>xuzhesums@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Sun Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Zhang, MD.</last_name>
      <phone>86-13902279690</phone>
      <email>zhangxisysu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhe Xu, MD.PHD.</last_name>
      <phone>86-13828453339</phone>
      <email>xuzhesums@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhe Xu, MD.PHD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://warfarindosing.org/Source/Home.aspx</url>
    <description>one of the best warfarin dose model</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xi Zhang</investigator_full_name>
    <investigator_title>Head of cardiac surgery</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>bleeding</keyword>
  <keyword>CYP2C9</keyword>
  <keyword>CYP4F2</keyword>
  <keyword>VKORC1</keyword>
  <keyword>warfarin dosing</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>pharmacogenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

